Value-Based Care

In a roundtable discussion hosted by HHS, health insurers pledged 6 key reforms they say are designed to cut red tape, accelerate care decisions, and enhance

Paula Aristizabal, MD, MAS, a pediatric hematologist/oncologist at Rady Children’s Hospital-San Diego/associate professor at the University of California San Diego, and her research team developed a peer navigation intervention known as the Childhood Malignancy Peer Research Navigation (Comprendo) program. This program pairs trained parent navigators—individuals who have experienced similar challenges with their own children’s cancer care—with parents who are newer to the experience, with the intention to guide these families through the informed consent process for childhood cancer clinical trials.

The specificity of ICD-10-CM codes allows providers to communicate correct clinical information to third-party payers and across the healthcare continuum.

An infusion of $95 million in Series C capital raise should enable a leading value cancer-care enabler to expand into new markets, invest in its existing oncology and health plan partnerships, and deepen its clinical value-based care model, according to a recently released press statement from Thyme Care.

The way value-based care needs to work in oncology is to pay the oncologist for managing all of the problems that occur with cancer and collaborating with other physicians to manage the noncancer illnesses.

The results of a recent survey commissioned by AccessOne, which focused on healthcare affordability and the impact of rising costs of living, revealed that the majority (71%) of consumers feel that inflation is having a significant effect on their healthcare purchasing decisions or their ability to pay medical bills.

Medicaid expansion under the Affordable Care Act was associated with significant increases in breast reconstruction surgery among non-Hispanic black women and women with lower income and education levels, according to results of a study presented during the American Society of Breast Surgeons 22nd Annual Meeting. At times, these increases achieved parity with non-Hispanic white women.

The demands of value-based care have continued to evolve since oncologists began transitioning from fee-for-service to fee-for-value reimbursement more than five years ago. For community-based oncology practices, more change is coming with the introduction of the Oncology Care First Model, the successor of the current Oncology Care Model (OCM). Following a one-year delay caused by the pandemic, the Centers for Medicare & Medicaid Services is expected to launch the Oncology Care First Model in 2022 and will likely include a larger number of practices than the OCM.

In recent years, the pace of innovation in healthcare has accelerated dramatically, ushering in new processes, therapies, technologies, and policies designed to increase efficiency, reduce waste, lower the cost of care, and improve clinical outcomes and quality of life for patients. However, along the way, stakeholders have encountered numerous obstacles that threaten to undermine the full potential of these advances. One of the most significant challenges is the fact that the development of innovation is frequently siloed, occurring within a specific subsector of the healthcare delivery ecosystem, with little consideration of the impact to other parts of the overall system.

Cellular immunotherapy was featured prominently during ASH 2020, with many presentations detailing deep and durable responses in a range of hematologic malignancies, mostly large B-cell lymphoma.